Recently, a group from Washington University in St. Louis (WU STL) reported on a first-in-man clinical trial e valuating neoantigen vaccine in patients with metastatic melanoma6. The researchers vaccinated thr ee patients IV with mature dend ritic cells presenting seven predicted mutation-specifi c HLA-A*02:01 restricted epitopes. They showed that vaccination with patient specific mutated epitopes augmented T cell immunity directed against naturally occurring dominant neoa ntigens and broadened the respo nse by revealing subdominant neoantigens. The initial priming dose they used was 1.5x107DC per peptide (9 peptides in total, 1.35X108DC total), and all the s ubsequent doses were 5.0x106DC per peptide (4.5X107DC total). In our trial, we plan t o load DC with a peptide pool co ntaining all defined epitopes recognized by TIL. Therefore, we chose a dose level similar to the doses used during the WUSTL trial for the IV administration. In a different phase I/I I clinical trial of sequential SQ and IV delivery of a dendritic cell vaccine for refractory multiple myeloma17, patients were vaccinated with increasing doses of 5 × -, 10× -, 50×106cells and 10× -, 50×106cells respectively. The treatment was well tolerated, and no severe a dverse events occurred. Therefore, we decided to vaccinate with DC doses which are not higher than 50×106for the SQ and the IV route of administration. We are planning to give the maximal dose possible according to our manufacturing yields to allow efficient activation of circulating and tissue resident neoantigen specific cells.